Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds

Completed · Phase 4

Conditions studied: HIV Infection, Hepatitis C

In brief

The chief purpose of this research is to evaluate interferon alpha sensitivity and cell type specific levels of interferon receptor and interferon stimulated genes and proteins in HIV/ HCV (hepatitis C virus) coinfected persons before and after administration of HIV medications (antiretroviral therapy).

Key facts

Study ID

NCT01285050

Run by

Johns Hopkins University

People needed

20

Starts

2011-01-01

Expected to finish

2015-04-01

Last updated by the study team

2016-11-29

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult Human
• Able to provide written informed consent
• HIV antibody positive
• HIV viral load positive
• HIV treatment naive
• Hepatitis C antibody positive
• Hepatitis C viral load positive
• Hepatitis C treatment naive
• Approved to take HIV medications for minimum 9 months
• Willing to use contraception, Life expectancy greater than 2 years

You may not qualify if…

• Significant opportunistic infections within 12 month
• Hepatitis B positive
• Evidence of liver cirrhosis
• Decompensated liver disease
• Chronic alcohol abuse
• Allergy to raltegravir, tenofovir, and/or emtricitabine
• Active or suspected malignancy
• Sarcoidosis
• Active TB
• Coronary artery disease
• Uncontrolled seizures
• Untreated thyroid disease
• Untreated diabetes
• Weight greater than 125 kg
• Severe depression or severe psychiatric disorder
• Ongoing alcohol or illicit drug use
• Pregnant, nursing, pr planning to become pregnant
• Allergy to interferon

Where it is running

• Johns Hopkins University — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.